D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution from the capital raise for the target ...
Fintel reports that on November 18, 2024, D. Boral Capital initiated coverage of Lineage Cell Therapeutics (NYSEAM:LCTX) with a Buy recommendation. As of October 22, 2024, the average one-year price ...
Flightcheck Commercial Aviation Services, a portfolio company of Lineage Capital, has acquired Keenan Technical Industries, a Connecticut-based provider of aircraft maintenance services. No financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback